Feature|Videos|December 10, 2024
Breaking barriers: EnzeneX™ to EnzeneX™ 2.0
Author(s)Enzene
Shilpa Gadgil, PhD (VP, Head of Process and Analytical Development, Head of CDMO Development) discusses Enzene's new technologies and the New Jersey site capabilities.
Shilpa Gadgil, PhD, from Enzene, discusses the company's Fully-Connected Continuous Manufacturing™ (FCCM™) platform and EnzeneX™ 2.0 for commercial biologics supply, as well as which large molecules have been successfully produced using the platforms. She also covers Enzene's new biologics site in New Jersey and the bottlenecks the company has overcome regarding transfer and scale-up.
Related Content
Trending on Pharmaceutical Technology
1
FDA Activity Round Up – July 2026
2
Brent Wilhelm on Why Drug Shortages Persist Despite Available Inventory
3
From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026
4
Midyear 2026 Check-In: Agentic AI Cuts Deviation Investigations by 50%
5